16.56
-0.49 (-2.87%)
| 前收盘价格 | 17.05 |
| 成交量 | 1,220,578 |
| 预期市盈率 (P/E Forward) | 189.56 |
| 价格/销量 (P/S) | 1.09 |
| 股市价格/股市净资产 (P/B) | 8.81 |
| 52周波幅 |
| 营业毛利率 | -18.71% |
| 营业利益率 (TTM) | -14.71% |
| 稀释每股收益 (EPS TTM) | -2.79 |
| 季度收入增长率 (YOY) | 22.30% |
| 总债务/股东权益 (D/E MRQ) | 320.75% |
| 流动比率 (MRQ) | 2.30 |
| 营业现金流 (OCF TTM) | 13.94 M |
| 杠杆自由现金流 (LFCF TTM) | 67.48 M |
| 资产报酬率 (ROA TTM) | -6.17% |
| 股东权益报酬率 (ROE TTM) | -92.31% |
新闻情绪
AIStockmoo 评分
| 价值 30% | -3.3 |
| 资本回报低于资本成本。资本回报下降。 参考 | |
| 负债高。盈利能力弱。短期流动性充足。现金流为正。 参考 | |
| 来自我们的 AI Insight 报告对预期回报与风险的评估。 参考 | NA |
| 相对估值 参考 | NA |
| 隐含增长 参考 | NA |
| 历史估值 参考 | NA |
| 持仓估值 参考 | NA |
| 风险溢价 参考 | NA |
| 市场估值 参考 | NA |
| 时机 30% | -1.7 |
| 过去一年没有明确趋势。股价远低于52周高点。 参考 | |
| 下降趋势,但均线已走平。 参考 | |
| 来自我们对走势图的 AI 技术分析。 参考 | NA |
| K线形态 参考 | NA |
| 市场情绪 20% | 0.9 |
| 近期没有目标价,因此依据目标价的调整方向。 参考 | |
| 近期新闻大多正面。 参考 | |
| 持仓情绪 参考 | NA |
| 聪明钱 20% | 0.9 |
| 多名内部人士近期净卖出。 参考 | |
| 机构在最新13F申报中净+8.37%的股份:140家增持,137家减持(截至30 Sep 2026的季度)。 参考 | |
| 空头持仓从31 Aug到30 Oct 2026变化+37.6%,回补天数7.6天(FINRA)。 参考 | |
| 市场和行业状况不佳。 | |
| 市场环境偏谨慎。 参考 | |
| 行业表现落后大市。 | |
| 各支柱方向一致,评分因此加强。 | |
| 不计入评分 | |
| 接近中期趋势线。 参考 | |
| 股价低于其52周平均水平。5年来下跌。 参考 | |
| 短期动能下降。 参考 | |
| 股价接近支撑位。 参考 | |
| 最终评分 | -1.36 |
市场趋势
| 短期 | 中期 | ||
| 行业 | Medical Devices (US) | 混合的 | 混合的 |
| Medical Devices (全球的) | 混合的 | 混合的 | |
| 股票 | Tandem Diabetes Care, Inc. | 混合的 | 看涨 |
相关股票
| 股票 | 市值 | DY | P/E(TTM) | P/B | 评分 |
|---|---|---|---|---|---|
| TNDM | - | - | - | 8.81 | -1.4 |
| BWAY | - | - | - | 4.62 | 0.4 |
| SSII | - | - | - | 6.11 | -2.0 |
| QTI | - | - | - | 9.14 | -5.0 |
| AXGN | - | - | - | 6.12 | 0.0 |
| ESTA | - | - | - | 128.59 | -1.7 |
|
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days. |
|
| 部门 | Healthcare |
| 行业 | Medical Devices |
| 投资方式 | Small Growth |
| 内部持股比例 | 0.95% |
| 机构持股比例 | 110.87% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| First Light Asset Management, Llc | 30 Sep 2026 | 3,251,835 |
| Gw&K Investment Management, Llc | 30 Sep 2026 | 2,903,529 |
| Longaeva Partners L.P. | 30 Sep 2026 | 2,358,636 |
| Exoduspoint Capital Management, Lp | 30 Sep 2026 | 2,079,371 |
| Millennium Management Llc | 30 Sep 2026 | 2,070,772 |
| Paradice Investment Management Llc | 30 Sep 2026 | 2,007,415 |
| Jennison Associates Llc | 30 Sep 2026 | 1,903,283 |
| Jacobs Levy Equity Management, Inc | 30 Sep 2026 | 1,890,510 |
该时间范围内无数据。
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| BEAVER SANDRA | - | - | 0 | 0 |
| CARPENTER RICK | - | 20.07 | -1,276 | -25,609 |
| GASSER ELIZABETH ANNE | - | 20.07 | -1,618 | -32,473 |
| HANSEN SHANNON MARIE | - | 20.07 | -1,535 | -30,807 |
| KYRILLOS JEAN-CLAUDE | 18.48 | 20.07 | -328 | -6,912 |
| MORRISON SUSAN | - | 20.07 | -810 | -16,257 |
| SHERIDAN JOHN F | - | 20.07 | -8,100 | -162,567 |
| VOSSELLER LEIGH | - | 20.07 | -1,479 | -29,684 |
| 累积净数量 | -15,146 | |||
| 累积净值 ($) | -304,309 | |||
| 累积平均购买 ($) | 18.48 | |||
| 累积平均卖出 ($) | 20.07 | |||
| 内部人员交易波幅 ($) | ||||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| KYRILLOS JEAN-CLAUDE | 职员 | 16 Nov 2026 | 获得 (+) | 207 | 18.48 | 3,825 |
| BEAVER SANDRA | 董事 | 15 Nov 2026 | 执行期权 | 6,747 | - | - |
| CARPENTER RICK | 职员 | 15 Nov 2026 | 处理 (-) | 1,276 | 20.07 | 25,609 |
| CARPENTER RICK | 职员 | 15 Nov 2026 | 执行期权 | 2,506 | - | - |
| GASSER ELIZABETH ANNE | 职员 | 15 Nov 2026 | 处理 (-) | 1,618 | 20.07 | 32,473 |
| GASSER ELIZABETH ANNE | 职员 | 15 Nov 2026 | 执行期权 | 3,014 | - | - |
| HANSEN SHANNON MARIE | 职员 | 15 Nov 2026 | 处理 (-) | 1,535 | 20.07 | 30,807 |
| HANSEN SHANNON MARIE | 职员 | 15 Nov 2026 | 执行期权 | 3,014 | - | - |
| KYRILLOS JEAN-CLAUDE | 职员 | 15 Nov 2026 | 处理 (-) | 535 | 20.07 | 10,737 |
| KYRILLOS JEAN-CLAUDE | 职员 | 15 Nov 2026 | 执行期权 | 1,009 | - | - |
| MORRISON SUSAN | 职员 | 15 Nov 2026 | 处理 (-) | 810 | 20.07 | 16,257 |
| MORRISON SUSAN | 职员 | 15 Nov 2026 | 执行期权 | 2,828 | - | - |
| SHERIDAN JOHN F | 董事 | 15 Nov 2026 | 处理 (-) | 8,100 | 20.07 | 162,567 |
| SHERIDAN JOHN F | 董事 | 15 Nov 2026 | 执行期权 | 15,917 | - | - |
| VOSSELLER LEIGH | 职员 | 15 Nov 2026 | 处理 (-) | 1,479 | 20.07 | 29,684 |
| VOSSELLER LEIGH | 职员 | 15 Nov 2026 | 执行期权 | 4,119 | - | - |
| 显示更多 | ||||||
机构
机构持股比例: 128.77%
| 持仓变动 | 机构数 | 股数 |
|---|---|---|
| 增持 | 140 | 17,373,437 |
| 减持 | 137 | 14,384,953 |
| 新建仓 | 42 | 6,940,860 |
| 清仓 | 46 | 4,068,138 |
来源:经Nasdaq的SEC 13F申报,最新申报截至30 Sep 2026。申报在每季结束后45天内陆续提交。
空头持仓
| 结算日 | 股数 | 回补天数 |
|---|---|---|
| 30 Oct 2026 | 16,171,009 | 7.6 |
| 15 Oct 2026 | 15,086,560 | 6.9 |
| 30 Sep 2026 | 13,369,091 | 5.2 |
| 15 Sep 2026 | 12,474,385 | 7.9 |
| 31 Aug 2026 | 11,753,819 | 8.2 |
| 14 Aug 2026 | 10,585,732 | 3.9 |
来源:经Nasdaq的FINRA空头持仓数据,每月公布两次。
| 日期 | 类型 | 细节 |
|---|---|---|
| 18 Nov 2026 | Yahoo Finance |
Tandem Diabetes shares climb 5% after Stifel upgrades stock to Buy
Investing.com -- Shares of Tandem Diabetes Care Inc (NASDAQ:TNDM) climbed 5.1% in premarket trading on Wednesday after Stifel upgraded the medical device maker to Buy from Hold, pointing to an improving margin trajectory and upcoming product catalysts. Analyst Jonathan Block also lifted his price… |
| 18 Nov 2026 | Yahoo Finance |
Insulet downgraded, Tandem Diabetes upgraded: Wall Street's top analyst calls
Insulet downgraded, Tandem Diabetes upgraded: Wall Street's top analyst calls… |
| 16 Nov 2026 | Yahoo Finance |
Tandem wins FDA clearance for tubeless automated insulin delivery system
The clearance tees up a 2027 launch of a product that analysts called Tandem’s “single most important commercial catalyst and growth driver.” |
| 13 Nov 2026 | Yahoo Finance |
Tandem Diabetes stock jumps 8% on FDA clearance for tubeless pump
Investing.com -- Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) rose 8% after the company announced U.S. Food and Drug Administration clearance for its Tandem Mobi insulin pump to operate as a tubeless automated insulin delivery system with up to seven days of wear. |
| 13 Nov 2026 | Yahoo Finance |
Tandem Mobi Now FDA Cleared as World’s First and Only Tubeless AID System with up to Seven Days of Wear
SAN DIEGO, November 13, 2026--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today announced U.S. Food and Drug Administration (FDA) clearance of Tandem Mobi for use as the world’s first and only tubeless automated insulin delivery system with… |
| 13 Nov 2026 | Yahoo Finance |
Can Tandem Diabetes Care (TNDM) Stay Cheap After Its Recall?
Tandem Diabetes Care has been through a bruising stretch, with the share price down about 87.2% over the past five years, and yet the business still commands meaningful attention in insulin pump therapy. With that kind of long term decline and fresh headlines around its devices, the question now is… |
| 12 Nov 2026 | Yahoo Finance |
Tandem Diabetes Care Receives Multiple Health Canada Approvals for t:slim X2 Insulin Pump
SAN DIEGO, November 12, 2026--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced receipt of Health Canada approval of a license amendment for the t:slim X2™ insulin pump with Control-IQ+™ automated insulin delivery (AID)… |
| 10 Nov 2026 | Yahoo Finance |
TNDM Q3 2026 deep dive: business model transition, product launches, and leadership change
Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) reported Q3 2026 results beating Wall Street’s revenue expectations, with sales up 13.8% year on year to $283.7 million. The company expects the full year’s revenue to be around $1.08 billion, close to analysts’ estimates. Its GAAP loss… |
| 07 Nov 2026 | Yahoo Finance |
Can Tandem Diabetes Care (TNDM) Justify Its Valuation As Q3 Earnings Beat And CEO Change Land?
Tandem Diabetes Care (TNDM) is back in focus after third quarter results showed higher sales, a much smaller net loss, reaffirmed full year revenue guidance, and a planned CEO transition to Jeannette Bankes. The latest Q3 update and the CEO transition have landed against a choppy backdrop for… |
| 06 Nov 2026 | Yahoo Finance |
What Tandem Diabetes Care (TNDM) Said on Its Q3 Earnings Call
Tandem Diabetes Care (NASDAQ:TNDM) reported 14% revenue growth in the third quarter of 2026, as higher pump shipments, pharmacy pricing and international sales helped lift gross margin. The company also announced a CEO transition and signaled that a slower-than-expected shift to pharmacy distributio… |
| 06 Nov 2026 | Yahoo Finance |
Tandem Diabetes Care names next CEO
Jeannette Bankes will take over the role from John Sheridan, who will retire at the end of the year after leading the company since 2019… |
| 06 Nov 2026 | Yahoo Finance |
Tandem Diabetes Care, Inc. Q3 2026 Earnings Call Summary
Moby summary of Tandem Diabetes Care, Inc.'s Q3 2026 earnings call… |
| 06 Nov 2026 | Yahoo Finance |
Tandem (TNDM) Q3 2026 Earnings Call Transcript
Sheridan steps down as CEO while Mobi Tubeless nears FDA clearance… |
| 06 Nov 2026 | Yahoo Finance |
Tandem Diabetes Care Inc (TNDM) Q3 2026 Earnings Call Highlights: Record Revenue and Pipeline ...
Tandem Diabetes Care Inc (TNDM) posts 14% revenue growth and record pump shipments while recalibrating 2027 outlook on slower pharmacy adoption and CEO transition. |
| 06 Nov 2026 | Yahoo Finance |
Earnings Beat Raises Fresh Questions For Tandem Diabetes Care Stock
Tandem Diabetes Care reported third quarter 2026 sales of US$283.69 million and a net loss of US$7.09 million, with earnings per share loss of US$0.10, and confirmed a CEO transition to Jeannette Bankes as John Sheridan prepares to retire. The combination of higher reported sales, reduced reported… |
| 显示更多 | ||
技术形态 中期
AI 技术分析
投资组合